On February 24, 2021 Kadmon Holdings, Inc. (NASDAQ:KDMN) reported that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present and host investor meetings at the following virtual investor conferences (Press release, Kadmon, FEB 24, 2021, View Source [SID1234575562]):
Raymond James 42nd Annual Institutional Investors Conference

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, March 3, 2021
Time: 4:40pm ET
H.C. Wainwright Global Life Sciences Conference

Presentation viewable starting on Tuesday, March 9, 2021 at 7:00am ET
Oppenheimer’s 31st Annual Healthcare Conference

Date: Wednesday, March 17, 2021
Time: 2:30pm ET
Live audio webcasts of the presentations may be accessed on the Investors section of the Kadmon website at www.kadmon.com. Replays of the webcasts will be available for 90 days.

On February 24, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET (Press release, Vertex Pharmaceuticals, FEB 24, 2021, https://investors.vrtx.com/news-releases/news-release-details/vertex-present-cowen-health-care-conference-march-2 [SID1234575561]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company’s website.

On February 24, 2021 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that management will participate in the following conferences in the month of March and invites investors to join by webcast (Press release, Oncternal Therapeutics, FEB 24, 2021, View Source [SID1234575559]). Please see details below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright: Global Life Sciences Conference (Virtual)
Title: Oncternal Therapeutics (ONCT) Company Presentation
Date: Tuesday, March 9th, 2021
Time: On demand, starting at 7:00 am Eastern Time
Presenter: James Breitmeyer, President & CEO
Webcasting Link: Here

Oppenheimer 31st Annual Healthcare Conference (Virtual)
Title: Oncternal Therapeutics (ONCT) Company Presentation
Date: Tuesday, March 16th, 2021
Time: 4:30 pm Eastern Time
Presenter: James Breitmeyer, President & CEO
Webcasting Link: Here
Webcasting Links:
Links to the webcasts along with replays will be accessible on the Events & Presentations page of the Investors section on the Company’s website at View Source

On February 24, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021 (Press release, Autolus, FEB 24, 2021, View Source [SID1234575558]). The company will also host one-on-one meetings with attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on-demand on the investor relations section of Autolus’ website at events starting March 9 at 7.00 a.m. EST. An archived replay will be available on the company’s website for a period of 90 days after the conference.

On February 24, 2021 ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference (Press release, ImmunoGen, FEB 24, 2021, View Source [SID1234575557]). The presentation will be available on-demand on March 9, 2021 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be accessible through the Investors and Media section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.